These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11926717)

  • 21. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder.
    Robert S; Hamner MB; Ulmer HG; Lorberbaum JP; Durkalski VL
    J Clin Psychiatry; 2006 Oct; 67(10):1522-6. PubMed ID: 17107242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning.
    Kasckow J; Lanouette N; Patterson T; Fellows I; Golshan S; Solorzano E; Zisook S
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):183-90. PubMed ID: 19711335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.
    Lam RW; Andersen HF
    Pharmacopsychiatry; 2006 Sep; 39(5):180-4. PubMed ID: 16944409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escitalopram versus venlafaxine XR in the treatment of depression.
    Montgomery SA; Andersen HF
    Int Clin Psychopharmacol; 2006 Sep; 21(5):297-309. PubMed ID: 16877901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Citalopram treatment of social anxiety disorder with comorbid major depression.
    Schneier FR; Blanco C; Campeas R; Lewis-Fernandez R; Lin SH; Marshall R; Schmidt AB; Sanchez-Lacay JA; Simpson HB; Liebowitz MR
    Depress Anxiety; 2003; 17(4):191-6. PubMed ID: 12820174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Citalopram treatment of fluoxetine-intolerant depressed patients.
    Calabrese JR; Londborg PD; Shelton MD; Thase ME
    J Clin Psychiatry; 2003 May; 64(5):562-7. PubMed ID: 12755660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
    Kennedy SH; Andersen HF; Thase ME
    Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression.
    Bent-Hansen J; Lunde M; Klysner R; Andersen M; Tanghøj P; Solstad K; Bech P
    Pharmacopsychiatry; 2003 Nov; 36(6):313-6. PubMed ID: 14663657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of citalopram in hospitalized adolescents with major depression: a preliminary, 8-week, fixed-dose, open-label, prospective study.
    Shoval G; Nahshoni E; Gothelf D; Manor I; Golobchik P; Zemishlany Z; Weizman A; Zalsman G
    Clin Neuropharmacol; 2011; 34(5):182-5. PubMed ID: 21926484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation.
    Grant JE; Potenza MN
    Int Clin Psychopharmacol; 2006 Jul; 21(4):203-9. PubMed ID: 16687991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison.
    Matreja PS; Badyal DK; Khosla P; Deswal RS
    Hum Psychopharmacol; 2007 Oct; 22(7):477-82. PubMed ID: 17647298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study.
    Souery D; Serretti A; Calati R; Oswald P; Massat I; Konstantinidis A; Linotte S; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    World J Biol Psychiatry; 2011 Aug; 12(5):364-75. PubMed ID: 21718212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naturalistic study of the early psychiatric use of citalopram in the United States.
    Rush AJ; Bose A; Heydorn WE
    Depress Anxiety; 2002; 16(3):121-7. PubMed ID: 12415537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.